



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

P7C3-A20

Cat. No.:	HY-15978
CAS No.:	1235481-90-9
Molecular Formula:	C ₂₂ H ₁₉ Br ₂ FN ₂ O
Molecular Weight:	506.21
Target:	Others
Pathway:	Others
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (197.55 mM)
 * "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		1.9755 mL	9.8773 mL	19.7546 mL
	5 mM		0.3951 mL	1.9755 mL	3.9509 mL
	10 mM		0.1975 mL	0.9877 mL	1.9755 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 3.85 mg/mL (7.61 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 2.5 mg/mL (4.94 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

P7C3-A20 is a derivative of P7C3 with potent proneurogenic and neuroprotective activity. P7C3-A20 exerts an antidepressant-like effect. P7C3-A20 can cross the blood-brain barrier and therefore has the potential for brain injury treatment^{[1][2][3]}.

In Vitro

P7C3-A20 (10-100 μM; 8 hours; PC12 cells) treatment alleviates oxygen-glucose deprivation (OGD)-induced cytotoxicity in PC12 cells^[1].
 P7C3-A20 (40-100 μM; 8 hours; PC12 cells) treatment alleviates OGD-induced apoptosis in PC12 cells^[1].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.
 Cell Viability Assay^[1]

	Cell Line:	PC12 cells
	Concentration:	10 μ M, 20 μ M, 40 μ M, 60 μ M, 80 μ M, 100 μ M
	Incubation Time:	8 hours
	Result:	Alleviated oxygen-glucose deprivation (OGD)-induced cytotoxicity in PC12 cells.
	Apoptosis Analysis ^[1]	
	Cell Line:	PC12 cells
	Concentration:	40 μ M, 60 μ M, 80 μ M, 100 μ M
	Incubation Time:	8 hours
	Result:	Alleviated oxygen-glucose deprivation (OGD)-induced apoptosis in PC12 cells.
In Vivo	P7C3-A20 (5-10 mg/kg; intraperitoneal injection; daily; for 7 days; Sprague-Dawley rats) treatment reduces infarct volume; reverses cell loss in the cortex and hippocampus and improves motor function without causing neurotoxicity in HI model rats. P7C3-A20 prevents HI-induced neuronal injury via activation of the PI3K/AKT/GSK3β signaling pathway^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Sprague-Dawley rats (200-250 g) induced hypoxic-ischemic (HI) injury ^[1]
	Dosage:	5 mg/kg, 10 mg/kg
	Administration:	Intraperitoneal injection; daily; for 7 days
	Result:	Reduced infarct volume; reversed cell loss in the cortex and hippocampus and improved motor function without causing neurotoxicity.

CUSTOMER VALIDATION

- Circ Res. 2021 May 28;128(11):1629-1641.
- Int J Mol Sci. 2023, 24(4), 3846.
- Neuroscience. 2020 Aug 10;441:197-208.
- Oxid Med Cell Longev. 2023 Feb 8;2023:7857760.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Blaya MO et al. Neuroprotective efficacy of a proneurogenic compound after traumatic brain injury. J Neurotrauma. 2014 Mar 1;31(5):476-86.
- [2]. Walker AK et al. The P7C3 class of neuroprotective compounds exerts antidepressant efficacy in mice by increasing hippocampal neurogenesis. Mol Psychiatry. 2015 Apr;20(4):500-8.
- [3]. Junjie Bai, et al. The Small Molecule P7C3-A20 Exerts Neuroprotective Effects in a Hypoxic-Ischemic Encephalopathy Model via Activation of PI3K/AKT/GSK3 β Signaling. Neuroscience. 2020 Jun 3;S0306-4522(20)30353-5.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA